A randomised controlled trial of lidocaine for post-traumatic and post-surgical neuropathic pain: Does dose or patient profile modify the outcome?
Grant Title
A randomised controlled trial of lidocaine for post-traumatic and post-surgical neuropathic pain: Does dose or patient profile modify the outcome?
Chief Investigator/s
ANZCA Area of Research
Pain Medicine
Project Summary
Intravenous lidocaine has been used for decades to treat refractory neuropathic pain, however there have only been a modest number of studies with low participant numbers, inconsistent doses and variation in protocols to treat neuropathic pain post trauma or surgery.
The significance of this pilot randomised comparison of dose and placebo is that it will immediately provide best-available evidence to inform which clinical dose achieves the best combination of reduced pain intensity at one week post infusion, weighed against the risk of adverse events for this cohort. The duration of analgesia (recorded up to 12 weeks post infusion) and the effect size for each dose will inform power calculations for larger subsequent clinical trials. Exploratory survival analysis with data from quantitative sensory testing and questionnaires will give new insight into mechanisms of effect and patient profiles that respond best to intravenous lidocaine. The battery of outcomes recorded will provide the foundation for judicious selection of a smaller number of key variables for subsequent clinical trials and evidence to support a priori hypotheses to test the associations between patient profile and response to lidocaine infusion.
The significance of this pilot randomised comparison of dose and placebo is that it will immediately provide best-available evidence to inform which clinical dose achieves the best combination of reduced pain intensity at one week post infusion, weighed against the risk of adverse events for this cohort. The duration of analgesia (recorded up to 12 weeks post infusion) and the effect size for each dose will inform power calculations for larger subsequent clinical trials. Exploratory survival analysis with data from quantitative sensory testing and questionnaires will give new insight into mechanisms of effect and patient profiles that respond best to intravenous lidocaine. The battery of outcomes recorded will provide the foundation for judicious selection of a smaller number of key variables for subsequent clinical trials and evidence to support a priori hypotheses to test the associations between patient profile and response to lidocaine infusion.
Grant Type
Novice Investigator Grant
Funding Year
2022
Funding Amount
$A19,902
Published Grant Details URL
Status
Approved